<DOC>
	<DOC>NCT00789191</DOC>
	<brief_summary>This trial is conducted in Asia, Europe and North America. This trial aims for comparison of the effect on the glycemic control in subjects with type 2 diabetes of basal insulin analogue with one oral anti-diabetic drug (OAD) versus oral anti-diabetic drug alone.</brief_summary>
	<brief_title>Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>Diagnosed with type 2 diabetes for at least 6 months before trial start Treatment with at least 1000 mg metformin per day for at least 3 months Insulinnaive (shortterm insulin treatment of up to 14 days is allowed) DPP4 (dipeptidyl peptidase4) inhibitor naive HbA1c (glycosylated haemoglobin A1c) between 7.510.0% by central laboratory analysis BMI (Body Mass Index) lesser than or equal to 45.0 kg/m2 Able and willing to take one subcutaneous injection every day Able and willing to perform mandatory SMPG (self measured plasma glucose) measurements Known or suspected allergy or intolerance to any of the trial products or related products Severe hypertension Treatment with thiazolidinedione (TZD) or GLP1 (glucagonlike peptide1) analogues within 2 months prior to trial start Cardiac disease, within the last 12 months Impaired hepatic function Impaired renal function Proliferative retinopathy or macular oedema requiring acute treatment Female of childbearing potential Known or suspected abuse of alcohol, narcotics or illicit substances</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>